Policies stymie stem cell progress

A new study confirms a seemingly obvious assumption about human embryonic stem cell research: Countries with fewer restrictions on research outperform countries with more restrictions. But the picture may be more complex than that, according to some experts. The article, published linkurl:online;http://www.cellstemcell.com/content/article/abstract?uid=PIIS1934590908002221 today (June 4) in Cell Stem Cell by linkurl:Aaron Levine;http://www.aarondlevine.net/ at the Georgia Institute of Technology

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
A new study confirms a seemingly obvious assumption about human embryonic stem cell research: Countries with fewer restrictions on research outperform countries with more restrictions. But the picture may be more complex than that, according to some experts. The article, published linkurl:online;http://www.cellstemcell.com/content/article/abstract?uid=PIIS1934590908002221 today (June 4) in Cell Stem Cell by linkurl:Aaron Levine;http://www.aarondlevine.net/ at the Georgia Institute of Technology, devised a metric to gauge the output of human embryonic stem cell (HESC) publications of 16 countries. Levine compared the number of HESC publications in each country with the number of RNAi publications -- for the study, RNAi publications acted as a type of control, representing an equally clinically relevant area of research, without the same controversy or discrepancies in policy as HESC research. Not surprisingly, "overperforming" countries including China, the United Kingdom, Israel, and Singapore, have historically permissive policies regarding HESC research, especially regarding the derivation of new stem cell lines. "Underperforming" countries, on the other hand, had more associated policy restrictions. But the study may not take into account other factors relating to HESC research beyond publication records, according to some experts. "Publications are one measure of performance focusing purely on the science," linkurl:Brian Salter,;http://www.kcl.ac.uk/schools/sspp/interdisciplinary/cbas/staff/acad/bs.html professor of politics and biomedicine at King's College London, told The Scientist in an Email. The study overlooked the role of other regulatory issues, he added, such as regulation of clinical experimentation and patenting, for example. It also does not take into account the hierarchy of journals and journal impact factors. "Underperforming countries may have scientists who go for the higher status journals." linkurl:Lori Knowles,;http://www.law.ualberta.ca/centres/hli/profiles/profile_knowles.html research fellow at the University of Alberta, told The Scientist that she would have liked to see a longer version of the article covering some of the other factors that might play into publication rates in various countries. Even adding factors such as citation rates and patents may not be enough, she added, noting that number of researchers per country or an explanation what different elements of HESC research that qualify (deriving new cell lines or cell reprogramming) are not included in the paper. "Measures like that in and of themselves are not completely [comprehensive]. So I felt that [Levine] might have something interesting in here, though I'm not sure that he's really convinced me that what he says lines up with the results he says he has."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Andrea Gawrylewski

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio